<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03688711</url>
  </required_header>
  <id_info>
    <org_study_id>ZP4207-17145</org_study_id>
    <nct_id>NCT03688711</nct_id>
  </id_info>
  <brief_title>Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus (T1DM) Compared to Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety&#xD;
      of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes&#xD;
      mellitus (T1DM) compared to placebo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were randomized in a ratio of 3:1 to receive a single subcutaneous dose of&#xD;
      dasiglucagon (0.6 mg) or matching placebo. Randomization also determined whether the subject&#xD;
      was to be injected in the buttock or deltoid. During the dosing visit (Visit 2), hypoglycemia&#xD;
      was induced by a fast-acting insulin glulisine (Apidra®) infusion, and trial drug was&#xD;
      administered when the subject's plasma glucose level was 45-60 mg/dL (2.5-3.3 mmol/L). During&#xD;
      the insulin-induced hypoglycemia, pharmacokinetic and pharmacodynamic samples were drawn, and&#xD;
      plasma glucose levels were monitored closely at site for safety reasons. A rescue glucose&#xD;
      infusion could be administered to ameliorate persistent hypoglycemia. Subjects were followed&#xD;
      for at least 28 days after dosing to perform an adequate immunogenicity evaluation of&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">March 11, 2019</completion_date>
  <primary_completion_date type="Actual">March 11, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Plasma Glucose Recovery.</measure>
    <time_frame>0-45 minutes after dosing</time_frame>
    <description>Plasma glucose recovery was defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic clamp procedure without administration of rescue intravenous (IV) glucose. Patients who received rescue IV glucose before 45 minutes and patients not recovering within 45 minutes after dosing were censored at 45 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Recovery After Trial Drug Injection</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
    <description>Plasma glucose recovery (patient has achieved increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L)) within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after trial drug injection without administration of rescue intravenous (IV) glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Changes From Baseline</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
    <description>Plasma glucose changes from baseline at 30 minutes, at 20 minutes, at 15 minutes, and at 10 minutes after trial drug injection or at the time of rescue (patient level).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Target Plasma Glucose Concentration</measure>
    <time_frame>0-45 minutes after dosing</time_frame>
    <description>Time to first plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) without administration of rescue intravenous glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Area Under the Effect Curve</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
    <description>Plasma glucose response as area under the effect curve (AUE) above baseline from time zero to 30 minutes, AUE0-30min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area Under the Plasma Concentration Curve</measure>
    <time_frame>0-90 minutes after dosing</time_frame>
    <description>Area under the drug concentration curve (AUC) from time zero to 90 minutes, AUC0-90min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area Under the Plasma Concentration Curve</measure>
    <time_frame>0-120 minutes after dosing</time_frame>
    <description>Area under the drug concentration curve (AUC) from time zero to 120 minutes, AUC0-120min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum Plasma Concentration</measure>
    <time_frame>0-120 minutes after dosing</time_frame>
    <description>Maximum plasma dasiglucagon concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Time to Maximum Plasma Concentration</measure>
    <time_frame>0-120 minutes after dosing</time_frame>
    <description>Time to maximum plasma dasiglucagon concentration (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Occurrence of Anti-drug Antibodies</measure>
    <time_frame>58 days</time_frame>
    <description>Occurrence of antibodies against dasiglucagon. Presented as percentage of patients with antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Infusions of IV Glucose After Trial Drug Administration</measure>
    <time_frame>0-45 minutes after dosing</time_frame>
    <description>Presented as number of patients with rescue infusions of IV glucose after trial drug administration. This was a safety outcome measure. IV = intravenous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Rescue Infusion of IV Glucose After Trial Drug Administration</measure>
    <time_frame>0-45 minutes after dosing</time_frame>
    <description>Safety outcome measure: time to first rescue infusion of IV glucose after trial drug administration. IV = intravenous</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Hypoglycemia</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Dasiglucagon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single fixed dose (subcutaneous injection) of dasiglucagon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single fixed dose (subcutaneous injection) of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasiglucagon</intervention_name>
    <description>Glucagon analogue</description>
    <arm_group_label>Dasiglucagon</arm_group_label>
    <other_name>ZP4207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for dasiglucagon</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo for dasiglucagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male subjects with T1DM for at least 1 year; diagnostic criteria as defined&#xD;
             by the American Diabetes Association (3).&#xD;
&#xD;
          -  Treated with insulin for T1DM for at least 1 year and with stable insulin treatment&#xD;
             (defined as no more than a 10-unit daily variation in total daily insulin dose) 30&#xD;
             days prior to screening&#xD;
&#xD;
          -  Hemoglobin A1c &lt;10%.&#xD;
&#xD;
          -  Aged between 18 and 75 years, both inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participation in a clinical trial within the dasiglucagon in the rescue&#xD;
             treatment of hypoglycemia program.&#xD;
&#xD;
          -  Known or suspected allergy to trial drug(s) or related products.&#xD;
&#xD;
          -  History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema).&#xD;
&#xD;
          -  Previous participation in this trial. Participation being defined by signing the&#xD;
             informed consent document.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina M Sylvest, MSc Pharm</last_name>
    <role>Study Director</role>
    <affiliation>Zealand Pharma A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ProSciento, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research, Inc.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <results_first_submitted>March 26, 2021</results_first_submitted>
  <results_first_submitted_qc>April 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2021</results_first_posted>
  <disposition_first_submitted>March 10, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 28, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 19, 2021</disposition_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glucagon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03688711/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03688711/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dasiglucagon 0.6 mg</title>
          <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>single fixed dose (subcutaneous injection) of placebo&#xD;
Placebo: Placebo for dasiglucagon</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety population of all randomized subjects who received at least one dose of trial drug</population>
      <group_list>
        <group group_id="B1">
          <title>Dasiglucagon 0.6 mg</title>
          <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>single fixed dose (subcutaneous injection) of placebo&#xD;
Placebo: Placebo for dasiglucagon</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" spread="13.49"/>
                    <measurement group_id="B2" value="36.5" spread="12.80"/>
                    <measurement group_id="B3" value="41.0" spread="13.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.49" spread="20.102"/>
                    <measurement group_id="B2" value="83.69" spread="10.812"/>
                    <measurement group_id="B3" value="84.30" spread="18.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg per square metre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.41" spread="5.802"/>
                    <measurement group_id="B2" value="27.92" spread="3.975"/>
                    <measurement group_id="B3" value="28.30" spread="5.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.5" spread="13.82"/>
                    <measurement group_id="B2" value="21.2" spread="13.42"/>
                    <measurement group_id="B3" value="22.2" spread="13.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Plasma Glucose Recovery.</title>
        <description>Plasma glucose recovery was defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic clamp procedure without administration of rescue intravenous (IV) glucose. Patients who received rescue IV glucose before 45 minutes and patients not recovering within 45 minutes after dosing were censored at 45 minutes.</description>
        <time_frame>0-45 minutes after dosing</time_frame>
        <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>single fixed dose (subcutaneous injection) of placebo&#xD;
Placebo: Placebo for dasiglucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Plasma Glucose Recovery.</title>
          <description>Plasma glucose recovery was defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic clamp procedure without administration of rescue intravenous (IV) glucose. Patients who received rescue IV glucose before 45 minutes and patients not recovering within 45 minutes after dosing were censored at 45 minutes.</description>
          <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="8.0" upper_limit="12.0"/>
                    <measurement group_id="O2" value="35.0" lower_limit="20.0" upper_limit="NA">The upper limit was not estimable due to insufficient number of participants reaching recovery</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The recovery rates of dasiglucagon and placebo were evaluated using a Kaplan Meier (KM) approach, with treatment group as a stratification factor. Differences between the KM curves (dasiglucagon versus placebo) were evaluated inferentially using pairwise two-sided log-rank tests stratified by injection site.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose Recovery After Trial Drug Injection</title>
        <description>Plasma glucose recovery (patient has achieved increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L)) within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after trial drug injection without administration of rescue intravenous (IV) glucose.</description>
        <time_frame>0-30 minutes after dosing</time_frame>
        <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>single fixed dose (subcutaneous injection) of placebo&#xD;
Placebo: Placebo for dasiglucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose Recovery After Trial Drug Injection</title>
          <description>Plasma glucose recovery (patient has achieved increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L)) within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after trial drug injection without administration of rescue intravenous (IV) glucose.</description>
          <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose recovery within 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose recovery within 20 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose recovery within 15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose recovery within 10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assessed at 30 minutes. The recovery rates of dasiglucagon and placebo were compared at each time point using a Fisher's exact test. Testing followed an a priori defined hierarchical inferential test order, proceeding until the first failure to reject the null hypothesis comparing dasiglucagon versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assessed at 20 minutes. The recovery rates of dasiglucagon and placebo were compared at each time point using a Fisher's exact test. Testing followed an a priori defined hierarchical inferential test order, proceeding until the first failure to reject the null hypothesis comparing dasiglucagon versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assessed at 15 minutes. The recovery rates of dasiglucagon and placebo were compared at each time point using a Fisher's exact test. Testing followed an a priori defined hierarchical inferential test order, proceeding until the first failure to reject the null hypothesis comparing dasiglucagon versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assessed at 10 minutes. The recovery rates of dasiglucagon and placebo were compared at each time point using a Fisher's exact test. Testing followed an a priori defined hierarchical inferential test order, proceeding until the first failure to reject the null hypothesis comparing dasiglucagon versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose Changes From Baseline</title>
        <description>Plasma glucose changes from baseline at 30 minutes, at 20 minutes, at 15 minutes, and at 10 minutes after trial drug injection or at the time of rescue (patient level).</description>
        <time_frame>0-30 minutes after dosing</time_frame>
        <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>single fixed dose (subcutaneous injection) of placebo&#xD;
Placebo: Placebo for dasiglucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose Changes From Baseline</title>
          <description>Plasma glucose changes from baseline at 30 minutes, at 20 minutes, at 15 minutes, and at 10 minutes after trial drug injection or at the time of rescue (patient level).</description>
          <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.29" spread="29.696"/>
                    <measurement group_id="O2" value="15.14" spread="9.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 20 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.95" spread="20.298"/>
                    <measurement group_id="O2" value="9.67" spread="8.846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.62" spread="17.077"/>
                    <measurement group_id="O2" value="5.23" spread="6.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.54" spread="12.560"/>
                    <measurement group_id="O2" value="0.62" spread="6.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline in plasma glucose at 30 minutes after investigational product injection was calculated using nominal sampling times and analyzed using an analysis of variance model with treatment, age group and injection site for each endpoint. Testing followed an a priori defined hierarchical inferential test order, proceeding until the first failure to reject the null hypothesis comparing dasiglucagon versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline in plasma glucose at 20 minutes after investigational product injection was calculated using nominal sampling times and analyzed using an analysis of variance model with treatment, age group and injection site for each endpoint. Testing followed an a priori defined hierarchical inferential test order, proceeding until the first failure to reject the null hypothesis comparing dasiglucagon versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline in plasma glucose at 15 minutes after investigational product injection was calculated using nominal sampling times and analyzed using an analysis of variance model with treatment, age group and injection site for each endpoint. Testing followed an a priori defined hierarchical inferential test order, proceeding until the first failure to reject the null hypothesis comparing dasiglucagon versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline in plasma glucose at 10 minutes after investigational product injection was calculated using nominal sampling times and analyzed using an analysis of variance model with treatment, age group and injection site for each endpoint. Testing followed an a priori defined hierarchical inferential test order, proceeding until the first failure to reject the null hypothesis comparing dasiglucagon versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Target Plasma Glucose Concentration</title>
        <description>Time to first plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) without administration of rescue intravenous glucose</description>
        <time_frame>0-45 minutes after dosing</time_frame>
        <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>single fixed dose (subcutaneous injection) of placebo&#xD;
Placebo: Placebo for dasiglucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Target Plasma Glucose Concentration</title>
          <description>Time to first plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) without administration of rescue intravenous glucose</description>
          <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="8.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="27.5" lower_limit="12.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Evaluated using a Kaplan Meier (KM) approach, with treatment group as a stratification factor, analogous to that used for the primary endpoint analysis. Differences between the KM curves (dasiglucagon versus placebo) were evaluated inferentially using pairwise two-sided log-rank tests. Subjects whose time to first plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) was not met within 45 minutes post-dosing were censored, at the time of the last valid plasma glucose measurement up to 45 minutes.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics - Area Under the Effect Curve</title>
        <description>Plasma glucose response as area under the effect curve (AUE) above baseline from time zero to 30 minutes, AUE0-30min.</description>
        <time_frame>0-30 minutes after dosing</time_frame>
        <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>single fixed dose (subcutaneous injection) of placebo&#xD;
Placebo: Placebo for dasiglucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics - Area Under the Effect Curve</title>
          <description>Plasma glucose response as area under the effect curve (AUE) above baseline from time zero to 30 minutes, AUE0-30min.</description>
          <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
          <units>hr*mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="8.41"/>
                    <measurement group_id="O2" value="2.67" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis was an analysis of covariance (ANCOVA) model with treatment group as factor and the baseline of the dependent variable plasma glucose as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.71</ci_lower_limit>
            <ci_upper_limit>6.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Area Under the Plasma Concentration Curve</title>
        <description>Area under the drug concentration curve (AUC) from time zero to 90 minutes, AUC0-90min</description>
        <time_frame>0-90 minutes after dosing</time_frame>
        <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Area Under the Plasma Concentration Curve</title>
          <description>Area under the drug concentration curve (AUC) from time zero to 90 minutes, AUC0-90min</description>
          <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
          <units>hr*pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1480" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Area Under the Plasma Concentration Curve</title>
        <description>Area under the drug concentration curve (AUC) from time zero to 120 minutes, AUC0-120min</description>
        <time_frame>0-120 minutes after dosing</time_frame>
        <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Area Under the Plasma Concentration Curve</title>
          <description>Area under the drug concentration curve (AUC) from time zero to 120 minutes, AUC0-120min</description>
          <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
          <units>hr*pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1780" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Maximum Plasma Concentration</title>
        <description>Maximum plasma dasiglucagon concentration (Cmax)</description>
        <time_frame>0-120 minutes after dosing</time_frame>
        <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Maximum Plasma Concentration</title>
          <description>Maximum plasma dasiglucagon concentration (Cmax)</description>
          <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
          <units>pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1350" spread="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Time to Maximum Plasma Concentration</title>
        <description>Time to maximum plasma dasiglucagon concentration (tmax)</description>
        <time_frame>0-120 minutes after dosing</time_frame>
        <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Time to Maximum Plasma Concentration</title>
          <description>Time to maximum plasma dasiglucagon concentration (tmax)</description>
          <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="15" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity - Occurrence of Anti-drug Antibodies</title>
        <description>Occurrence of antibodies against dasiglucagon. Presented as percentage of patients with antibodies.</description>
        <time_frame>58 days</time_frame>
        <population>The safety analysis set of all randomized subjects who received at least one dose of trial drug (same as the full analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>single fixed dose (subcutaneous injection) of placebo&#xD;
Placebo: Placebo for dasiglucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity - Occurrence of Anti-drug Antibodies</title>
          <description>Occurrence of antibodies against dasiglucagon. Presented as percentage of patients with antibodies.</description>
          <population>The safety analysis set of all randomized subjects who received at least one dose of trial drug (same as the full analysis set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Infusions of IV Glucose After Trial Drug Administration</title>
        <description>Presented as number of patients with rescue infusions of IV glucose after trial drug administration. This was a safety outcome measure. IV = intravenous</description>
        <time_frame>0-45 minutes after dosing</time_frame>
        <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>single fixed dose (subcutaneous injection) of placebo&#xD;
Placebo: Placebo for dasiglucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Infusions of IV Glucose After Trial Drug Administration</title>
          <description>Presented as number of patients with rescue infusions of IV glucose after trial drug administration. This was a safety outcome measure. IV = intravenous</description>
          <population>The full analysis set of all randomized subjects who received at least one dose of trial drug (same as the safety analysis set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Rescue Infusion of IV Glucose After Trial Drug Administration</title>
        <description>Safety outcome measure: time to first rescue infusion of IV glucose after trial drug administration. IV = intravenous</description>
        <time_frame>0-45 minutes after dosing</time_frame>
        <population>Only the patients who received IV glucose administration are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>single fixed dose (subcutaneous injection) of placebo&#xD;
Placebo: Placebo for dasiglucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Rescue Infusion of IV Glucose After Trial Drug Administration</title>
          <description>Safety outcome measure: time to first rescue infusion of IV glucose after trial drug administration. IV = intravenous</description>
          <population>Only the patients who received IV glucose administration are included.</population>
          <units>minutes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dasiglucagon 0.6 mg</title>
          <description>single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
Dasiglucagon: Glucagon analogue</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>single fixed dose (subcutaneous injection) of placebo&#xD;
Placebo: Placebo for dasiglucagon</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Kim Mark Knudsen</name_or_title>
      <organization>Zealand Pharma A/S</organization>
      <phone>+4550603780</phone>
      <email>KMKnudsen@zealandpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

